GPC Biotech Announces Clearance to Initiate Additional Phase 1 Clinical Trial with 1D09C3 Anticancer Monoclonal Antibody
10-Nov-2005 -
GPC Biotech AG announced that it had received clearance from the Paul-Ehrlich-Institut (PEI) to initiate human clinical testing in Germany with the 1D09C3 anticancer monoclonal antibody. The PEI is the German national agency responsible for regulating biological and blood products.
The study is ...
clinical trials
dosing
Germany
+8